Lilly to acquire DICE Therapeutics for approximately $2.4B

Indianapolis and South San Francisco, CA, June 20, 2023 (PRNewswire) -- Lilly announced the acquisition of DICE Therapeutics, a biopharmaceutical company known for its groundbreaking DELSCAPE technology platform. The strategic move aims to bolster Lilly's efforts in developing novel oral therapeutic candidates to address the urgent medical needs of patients suffering from chronic immunological conditions, marking a significant advancement in the field.

Read full article here.